CL2015002125A1 - Moduladores de receptores nmda de espiro-lactama y sus usos. - Google Patents

Moduladores de receptores nmda de espiro-lactama y sus usos.

Info

Publication number
CL2015002125A1
CL2015002125A1 CL2015002125A CL2015002125A CL2015002125A1 CL 2015002125 A1 CL2015002125 A1 CL 2015002125A1 CL 2015002125 A CL2015002125 A CL 2015002125A CL 2015002125 A CL2015002125 A CL 2015002125A CL 2015002125 A1 CL2015002125 A1 CL 2015002125A1
Authority
CL
Chile
Prior art keywords
lactam
spiro
modulators
nmda receptors
nmda
Prior art date
Application number
CL2015002125A
Other languages
English (en)
Inventor
John A Lowe
M Amin Khan
Original Assignee
Aptinyx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aptinyx Inc filed Critical Aptinyx Inc
Publication of CL2015002125A1 publication Critical patent/CL2015002125A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

COMPUESTOS DERIVADOS DE ESPIRO-LACTAMA, AGONISTAS PARCIALES DEL RECEPTOR NMDA; COMPOSICION FARMACEUTICA QUE LOS COMPRENDE; UTILES EN EL TRATAMIENTO DE ENFERMEDADES TALES COMO ALZHEIMER, ESQUIZOFRENIA, ANSIEDAD, ENTRE OTRAS.
CL2015002125A 2013-01-29 2015-07-29 Moduladores de receptores nmda de espiro-lactama y sus usos. CL2015002125A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361757903P 2013-01-29 2013-01-29

Publications (1)

Publication Number Publication Date
CL2015002125A1 true CL2015002125A1 (es) 2015-12-04

Family

ID=50071821

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2015002121A CL2015002121A1 (es) 2013-01-29 2015-07-29 Modulares de receptores nmda de espiro-lactama y sus usos.
CL2015002125A CL2015002125A1 (es) 2013-01-29 2015-07-29 Moduladores de receptores nmda de espiro-lactama y sus usos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2015002121A CL2015002121A1 (es) 2013-01-29 2015-07-29 Modulares de receptores nmda de espiro-lactama y sus usos.

Country Status (28)

Country Link
US (8) US9512134B2 (es)
EP (2) EP3514158B1 (es)
JP (2) JP2016506958A (es)
KR (1) KR102280616B1 (es)
CN (1) CN105229011B (es)
AU (1) AU2014212484B2 (es)
BR (1) BR112015018087B1 (es)
CA (1) CA2898861C (es)
CL (2) CL2015002121A1 (es)
CY (1) CY1121675T1 (es)
DK (1) DK2951183T3 (es)
EA (1) EA032649B1 (es)
ES (2) ES2935352T3 (es)
HK (1) HK1218417A1 (es)
HR (2) HRP20221545T1 (es)
HU (1) HUE043843T2 (es)
IL (1) IL240163B (es)
LT (2) LT3514158T (es)
MX (1) MX2015009786A (es)
MY (1) MY188450A (es)
PE (1) PE20151416A1 (es)
PH (1) PH12015501601B1 (es)
PL (1) PL2951183T3 (es)
PT (2) PT3514158T (es)
SG (1) SG11201505860XA (es)
SI (2) SI2951183T1 (es)
TR (1) TR201908596T4 (es)
WO (1) WO2014120783A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101769999B1 (ko) 2008-09-18 2017-08-21 노오쓰웨스턴 유니버시티 Ｎｍｄａ 수용체 조절제 및 그의 용도
CN105308049A (zh) 2013-01-29 2016-02-03 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
SG11201505942YA (en) 2013-01-29 2015-08-28 Naurex Inc Spiro-lactam nmda receptor modulators and uses thereof
EP3514158B1 (en) 2013-01-29 2022-10-12 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CN105229010A (zh) * 2013-01-29 2016-01-06 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
AU2014212490A1 (en) 2013-01-29 2015-07-30 Aptinyx, Inc. Spiro-lactam NMDA receptor modulators and uses thereof
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CN109415372B (zh) * 2016-05-19 2021-01-15 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
EP3490994B8 (en) 2016-08-01 2024-03-13 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
US10918637B2 (en) * 2016-08-01 2021-02-16 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
WO2018026798A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda modulators and methods of using same
SG11201900558RA (en) 2016-08-01 2019-02-27 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof
WO2018026779A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2019152688A1 (en) * 2018-01-31 2019-08-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
US11578072B2 (en) 2018-01-31 2023-02-14 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
WO2019152685A1 (en) * 2018-01-31 2019-08-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and methods of using same
WO2019152696A1 (en) * 2018-01-31 2019-08-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
PE20211455A1 (es) * 2018-01-31 2021-08-05 Aptinyx Inc Moduladores del receptor nmda espiro-lactama y usos de los mismos
WO2020263848A1 (en) 2019-06-24 2020-12-30 Naurex Inc. Processes and intermediates for producing diazaspiro lactam compounds
AU2020304001A1 (en) * 2019-06-24 2022-01-27 Naurex Inc. Solid forms of tert-butyl (S)-2-((2S,3R) -1-amino-3-hydroxy-1-oxobu tan-2-yl)-1-oxo-2, 5-diazaspiro [3.4] octan e-5-carboxylate and methods of preparing them
WO2021021996A1 (en) * 2019-08-01 2021-02-04 Aptinyx Inc. Methods of treating disorders associated with elevated levels of antibodies that interact with the nmda receptor
CN113956183B (zh) * 2021-10-28 2023-06-20 成都市科隆化学品有限公司 一种Boc-Ser(Bzl)-OH及其制备方法

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0180398A1 (en) 1984-10-26 1986-05-07 The Regents Of The University Of California Synthesis of beta-lactam
CA1305177C (en) 1987-06-30 1992-07-14 Yasufumi Ohfune Carboxycyclopropylglycine and process for producing the same
US4904681A (en) 1987-12-01 1990-02-27 G. D. Searle & Co. D-cycloserine and its prodrugs as cognitive enhancers
EP0360390A1 (en) 1988-07-25 1990-03-28 Glaxo Group Limited Spirolactam derivatives
US5061721A (en) 1989-03-15 1991-10-29 G. D. Searle & Co. Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5086072A (en) 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
WO1992007561A1 (fr) 1990-10-30 1992-05-14 Ss Pharmaceutical Co., Ltd. Preparation d'un gel anti-inflammatoire et analgesique
US5168103A (en) 1991-01-22 1992-12-01 American Home Products Corporation [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives
FR2692268B1 (fr) 1992-06-15 1994-08-19 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activité de récepteur NMDA, acides nucléiques codant pour ces polypeptides et utilisations.
SE9301667D0 (sv) 1993-05-14 1993-05-14 Kabi Pharmacia Ab New use
US5523323A (en) 1993-09-14 1996-06-04 Maccecchini; Maria-Luisa Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
US5605911A (en) 1995-01-31 1997-02-25 Washington University Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH)
US6335358B1 (en) 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
US5741778A (en) 1996-03-19 1998-04-21 Amgen Inc. Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product
US5763393A (en) 1996-05-17 1998-06-09 Neurotherapeutics L.P. Neuroactive peptides
IL127332A0 (en) 1996-06-07 1999-09-22 Zeneca Ltd Peptide derivatives
EP0918859A1 (en) 1996-08-02 1999-06-02 ZymoGenetics, Inc. Testis-specific insulin homolog polypeptides
US5902815A (en) 1996-09-03 1999-05-11 Washington University Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
JP3955345B2 (ja) 1996-09-27 2007-08-08 サントリー株式会社 新規アミノ酸ダイジハーベイン
AU1585999A (en) 1997-11-12 1999-05-31 Neurotherapeutics Methods for the detection and treatment of disease using a glycosyltransferase
US5952389A (en) 1998-01-13 1999-09-14 Synchroneuron Methods of treating tardive dyskinesia and other movement disorders
US6007841A (en) 1998-03-13 1999-12-28 Algos Pharmaceutical Corporation Analgesic composition and method for treating pain
US6274314B1 (en) 1998-04-02 2001-08-14 Nyxis Neurotherapies, Inc. Diagnostic assay for the modified nucleosides pseudouridine, 7-methyladenosine, or 1-methyladenosine
US6197820B1 (en) 1998-04-06 2001-03-06 Uab Research Foundation Use of phenylglycine derivatives to decrease neuronal death caused by brain tumors and brain lesions
US6025471A (en) 1998-06-03 2000-02-15 Deghenghi; Romano Diazaspiro, azepino and azabicyclo therapeutic peptides
WO2000028090A2 (en) 1998-11-12 2000-05-18 Nyxis, Inc. Diagnostic assay for cancer
US20030064921A1 (en) 1999-10-27 2003-04-03 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor ligand binding and activity
AU1922301A (en) 1999-11-17 2001-05-30 Nyxis Neurotherapies, Inc. Differential gene expression in cancer
JP2003521247A (ja) 2000-02-01 2003-07-15 エージーワイ セラピューティクス インコーポレーテッド Ｎｍｄａ受容体のプロテインチロシンホスファターゼとの相互作用
WO2001096606A2 (en) 2000-06-14 2001-12-20 Nyxis Neurotherapies, Inc. Identification of genes and compounds for treatment of cancer
JP2004500874A (ja) 2000-06-22 2004-01-15 ニクシス　ニューロセラピーズ　インコーポレーティッド 低酸素症および関連状態の治療のための神経活性ペプチド
GB0018272D0 (en) 2000-07-25 2000-09-13 Vernalis Research Limited Chemical compounds IV
IL145209A0 (en) 2000-09-06 2002-06-30 Pfizer Prod Inc Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
EP1186303A3 (en) 2000-09-06 2003-12-10 Pfizer Products Inc. Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist
UA73619C2 (en) 2000-12-13 2005-08-15 Pfizer Prod Inc Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment
US20020142287A1 (en) 2000-12-14 2002-10-03 Hirotaka Yamamoto High throughput assay to detect inhibitors of the map kinase pathway
US20030065138A1 (en) 2001-03-07 2003-04-03 University Of Utah Research Foundation Linear gamma-carboxyglutamate rich conotoxins
AU2002255705A1 (en) 2001-03-12 2002-09-24 Nyxis Neurotherapies, Inc Neuroactive peptides for prevention and/or treatment of hypoxia and neuropathic pain
US20030022253A1 (en) 2001-07-25 2003-01-30 Nyxis Neurotherapies, Inc. Method for identifying, isolating and producing neuroactive binding agents and binding agents derived thereby
DE60330456D1 (de) 2002-07-05 2010-01-21 Targacept Inc N-aryl diazaspirozyklische verbindungen, deren verwendung und das verfahren zu ihren herstellung
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
EP1660634A4 (en) 2003-08-08 2009-02-18 Burnham Inst P16-mediated regulation of NMDA receptors
US7662856B2 (en) 2003-08-29 2010-02-16 The University Of Houston System Compositions having antimycrobial activity including a hydroxamate or a hydroxamate and a hydroxlyamine
GB0323204D0 (en) 2003-10-03 2003-11-05 Novartis Ag Organic compounds
US20050096311A1 (en) 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders
US20060063707A1 (en) 2004-09-17 2006-03-23 Lifelike Biomatic, Inc. Compositions for enhancing memory and methods therefor
PL1868614T3 (pl) 2005-03-24 2013-01-31 Univ Emory Schemat dawkowania do leczenia urazowego uszkodzenia mózgu progesteronem
WO2007025141A2 (en) 2005-08-26 2007-03-01 Wisconsin Alumni Research Foundation Poly-beta-peptides from functionalized beta-lactam monomers and antibacterial compositions containing same
AR059224A1 (es) * 2006-01-31 2008-03-19 Jerini Ag Compuestos para la inhibicion de integrinas y uso de estas
WO2007103719A2 (en) 2006-03-03 2007-09-13 Incyte Corporation MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
WO2008033464A2 (en) 2006-09-15 2008-03-20 Schering Corporation Azetidinone derivatives for the treatment of disorders of the lipid metabolism
JP2008188285A (ja) 2007-02-06 2008-08-21 Bridgestone Corp バックパッド及び車両用シート
CN101066945B (zh) 2007-05-25 2010-05-19 中国科学院上海有机化学研究所 一种合成3-位取代内酰胺类化合物的方法
CN101125817B (zh) 2007-08-03 2011-09-14 中国科学院上海有机化学研究所 一种合成高对映选择性醛基取代小环胺类化合物和光学活性3-位取代内酰胺类化合物的方法
WO2009039390A2 (en) 2007-09-20 2009-03-26 Naurex Inc. The development of glycobiology-based therapeutics for the treatment of brain tumors
WO2009105718A1 (en) 2008-02-20 2009-08-27 The Children's Hospital Of Philadelphia Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatmemt of autism
JP2011525521A (ja) 2008-06-27 2011-09-22 ノイロサーチ アクティーゼルスカブ 新規なテトラメチル置換ピペリジン誘導体及びモノアミン神経伝達物質再取り込み阻害薬としてのそれらの使用
CN102112442B (zh) 2008-08-07 2014-12-10 弗·哈夫曼-拉罗切有限公司 制备大环的方法
GB0814991D0 (en) 2008-08-15 2008-09-24 Glaxo Group Ltd Compounds
KR101769999B1 (ko) 2008-09-18 2017-08-21 노오쓰웨스턴 유니버시티 Ｎｍｄａ 수용체 조절제 및 그의 용도
WO2010065709A2 (en) 2008-12-03 2010-06-10 Amin Khan Hydroxamic acid derivatives, preparation and therapeutic uses thereof
DE102009001460B4 (de) 2009-03-11 2010-12-02 Zf Friedrichshafen Ag Ölbehälter
US20120178695A1 (en) 2009-07-02 2012-07-12 Joseph Moskal Methods of treating neuropathic pain
HUE043807T2 (hu) 2009-10-05 2019-09-30 Univ Northwestern GLYX Alzheimer-kór, Parkinson-kór vagy Huntington-kór kezelésében történõ alkalmazásra
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
CA2789331C (en) 2010-02-11 2017-11-07 Northwestern University Secondary structure stabilized nmda receptor modulators and uses thereof
AR082633A1 (es) 2010-08-12 2012-12-19 Tetraphase Pharmaceuticals Inc Analogos de tetraciclina
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
KR20190037359A (ko) 2011-04-27 2019-04-05 노오쓰웨스턴 유니버시티 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법
CN103635264B (zh) 2011-06-27 2016-06-01 皇家飞利浦有限公司 超声换能组件及其制造方法
CA2881993C (en) 2011-07-27 2017-05-09 Astrazeneca Ab Substituted 4-methoxy-n3-(pyrimidin-2-yl)benzene-1,3-diamine compounds, and salts thereof
CN105229010A (zh) 2013-01-29 2016-01-06 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
CN105308049A (zh) 2013-01-29 2016-02-03 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
AU2014212490A1 (en) 2013-01-29 2015-07-30 Aptinyx, Inc. Spiro-lactam NMDA receptor modulators and uses thereof
SG11201505942YA (en) 2013-01-29 2015-08-28 Naurex Inc Spiro-lactam nmda receptor modulators and uses thereof
EP3514158B1 (en) 2013-01-29 2022-10-12 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CN109415372B (zh) 2016-05-19 2021-01-15 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
US10918637B2 (en) 2016-08-01 2021-02-16 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
EP3490994B8 (en) 2016-08-01 2024-03-13 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
WO2018026779A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
SG11201900558RA (en) 2016-08-01 2019-02-27 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof
WO2018026798A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda modulators and methods of using same

Also Published As

Publication number Publication date
TR201908596T4 (tr) 2019-07-22
JP6564513B2 (ja) 2019-08-21
SI2951183T1 (sl) 2019-07-31
US9504670B2 (en) 2016-11-29
CA2898861A1 (en) 2014-08-07
US20160368926A1 (en) 2016-12-22
US10441571B2 (en) 2019-10-15
SG11201505860XA (en) 2015-08-28
JP2016506958A (ja) 2016-03-07
US20180250268A1 (en) 2018-09-06
EA032649B1 (ru) 2019-06-28
US9512134B2 (en) 2016-12-06
HRP20221545T1 (hr) 2023-03-03
BR112015018087A2 (pt) 2017-07-18
WO2014120783A1 (en) 2014-08-07
JP2019019133A (ja) 2019-02-07
US20160122359A1 (en) 2016-05-05
PL2951183T3 (pl) 2019-08-30
EP2951183A1 (en) 2015-12-09
PT2951183T (pt) 2019-06-17
NZ709870A (en) 2020-09-25
US20170231956A1 (en) 2017-08-17
AU2014212484A1 (en) 2015-07-30
PT3514158T (pt) 2023-01-13
PE20151416A1 (es) 2015-10-10
KR102280616B1 (ko) 2021-07-21
AU2014212484B2 (en) 2018-01-04
HUE043843T2 (hu) 2019-09-30
EA201591401A1 (ru) 2018-01-31
IL240163B (en) 2020-02-27
PH12015501601A1 (en) 2015-10-19
CL2015002121A1 (es) 2015-12-04
DK2951183T3 (da) 2019-06-03
CN105229011B (zh) 2018-02-06
US20200206189A1 (en) 2020-07-02
IL240163A0 (en) 2015-09-24
US20220151992A1 (en) 2022-05-19
HK1218417A1 (zh) 2017-02-17
US10052308B2 (en) 2018-08-21
US9579304B2 (en) 2017-02-28
EP3514158A1 (en) 2019-07-24
US10441572B2 (en) 2019-10-15
LT2951183T (lt) 2019-05-27
LT3514158T (lt) 2023-02-10
EP3514158B1 (en) 2022-10-12
US11077094B2 (en) 2021-08-03
HRP20190613T1 (hr) 2019-06-28
BR112015018087B1 (pt) 2022-09-20
MY188450A (en) 2021-12-09
ES2935352T3 (es) 2023-03-06
MX2015009786A (es) 2015-12-11
CA2898861C (en) 2021-07-20
KR20150110790A (ko) 2015-10-02
PH12015501601B1 (en) 2015-10-19
ES2734405T3 (es) 2019-12-05
CN105229011A (zh) 2016-01-06
US20160289240A1 (en) 2016-10-06
BR112015018087A8 (pt) 2021-06-22
EP2951183B1 (en) 2019-03-13
US20180250267A1 (en) 2018-09-06
SI3514158T1 (sl) 2023-03-31
CY1121675T1 (el) 2020-07-31

Similar Documents

Publication Publication Date Title
CL2015002125A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
CL2015002123A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
CL2016001983A1 (es) Compuestos aza bicíclicos como agonistas del receptor muscarínico m1 y/o m4
CO2018006662A2 (es) Agonistas del receptor de apelina y métodos de uso
CL2017001289A1 (es) Compuestos bicíclicos fusionados, sus composiciones y su uso para el tratamiento de enfermedades relacionadas con la modulación del receptor x farnesoide (fxr).
ECSP16061758A (es) Moduladores de tetrahidropiridopirazinas de gpr6
CR20150664A (es) Moduladores de los receptores de estrógeno y sus usos
CL2018003265A1 (es) Modulares del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos.
UY36311A (es) Indazoles sustituidos con bencilo
CL2018000953A1 (es) 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj)
DOP2016000145A (es) Reguladores de nrf2
UY35485A (es) Compuestos heterocíclicos y usos de los mismos
EA201791310A1 (ru) Химерные антигенные рецепторы к bcma
CL2015002222A1 (es) Compuestos de azabencimidazol como inhibidores de isoenzimas pde4 para el tratamiento del snc y otros trastornos.
CL2015002124A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
ECSP18049420A (es) Composiciones novedosas, usos y métodos para hacerlas
NI201400079A (es) Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UY37026A (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apj
UY35469A (es) Moduladores de p2x7
GT201800020A (es) Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r)
GT201300196A (es) Moduladores del receptor de glucagón
CL2015000976A1 (es) Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados.
UY35653A (es) Nuevos derivados de indol y de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UY36209A (es) Derivados de la pirazina como agonistas moduladores del receptor gpr40 y composiciones farmacéuticas que los contienen
DOP2017000058A (es) Derivados de tetrahidroquinolina como inhibidores del bromodominio